Bristol Myers got the first TYK2 approval. Frazier’s new biotech Sudo hopes to get many more
Earlier in September, the FDA approved a TYK2 inhibitor for the first time, a drug from Bristol Myers Squibb for psoriasis, without slapping on the black box safety warning that has cast a shadow on the larger family of anti-inflammatory drugs it comes from, the JAK inhibitors.
While Bristol Myers won the first approval, it’s followed by a suite of others with TYK2 programs. Now, Frazier’s joining the fray.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.